|Bid||75.52 x 1200|
|Ask||75.43 x 900|
|Day's range||71.75 - 76.44|
|52-week range||23.81 - 77.45|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||29.58|
|Earnings date||05 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||91.20|
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,770,000 ordinary shares. The offering is expected to close on or about August 11, 2020, subject to customary closing conditions.
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the 2020 Fortune Best Workplaces for Millennials™ list. Horizon ranked 7th among 25 companies in the small and medium company category in its first year on the list.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is offering to sell $700,000,000 of its ordinary shares in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional $105,000,000 of ordinary shares in the public offering.